| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA …
Over the last 12 months, insiders at TransCode Therapeutics, Inc. have bought $0 and sold $0 worth of TransCode Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at TransCode Therapeutics, Inc. have bought $133,068 and sold $0 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 98,000 shares for transaction amount of $49,980 was made by Dudley Robert Michael (Chief Executive Officer) on 2023‑09‑28.
| 2023-09-28 | Dudley Robert Michael | Chief Executive Officer | 98,000 4.2888% | $0.51 | $49,980 | -96.46% | ||
| 2023-09-28 | Fitzgerald Thomas A | Chief Financial Officer | 49,350 2.1597% | $0.51 | $25,169 | -96.46% | ||
| 2023-06-21 | Dudley Robert Michael | Chief Executive Officer | 12,000 0.0815% | $2.65 | $31,818 | -93.94% | ||
| 2023-06-20 | Dudley Robert Michael | Chief Executive Officer | 6,607 0.0443% | $2.55 | $16,847 | -93.73% | ||
| 2023-06-09 | Dudley Robert Michael | Chief Executive Officer | 19,000 0.131% | $2.76 | $52,440 | -93.23% | ||
| 2022-09-14 | Dudley Robert Michael | Chief Executive Officer | 20,000 0.1541% | $1.15 | $23,000 | -73.09% | ||
| 2022-06-16 | Fitzgerald Thomas A | Chief Financial Officer | 12,000 0.0932% | $1.27 | $15,240 | -63.79% | ||
| 2022-05-27 | Dudley Robert Michael | Chief Executive Officer | 28,000 0.2175% | $1.84 | $51,643 | -73.35% |
| Increased Positions | 2 | +20% | 3,709 | +25.7% |
| Decreased Positions | 3 | -30% | 14,263 | -98.82% |
| New Positions | <1 | New | 2,964 | New |
| Sold Out Positions | 3 | Sold Out | 14,263 | Sold Out |
| Total Postitions | 9 | -10% | 3,880 | -73.12% |
| Drw Securities, Llc | $87.00 | 1.17% | 11,702 | +11,702 | New | 2025-09-30 |
| Citigroup Inc | $12.00 | 0.16% | 1,586 | +1,586 | New | 2025-09-30 |
| Federation Des Caisses Desjardins Du Quebec | $7.00 | 0.1% | 975 | +975 | New | 2025-09-30 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.01% | 142 | -260 | -64.68% | 2025-09-30 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 10 | 0 | 0% | 2025-09-30 |
| Royal Bank Of Canada | $0 | <0.01% | 8 | 0 | 0% | 2025-09-30 |
| Bank Of America Corp /De/ | $0 | <0.01% | 8 | 0 | 0% | 2025-09-30 |
| Osaic Holdings, Inc. | $0 | 0% | 3 | 0 | 0% | 2025-09-30 |
| Fmr Llc | $0 | 0% | 0 | -3 | Sold Out | 2025-09-30 |
| Goldman Sachs Group Inc | $0 | 0% | 0 | -28,042 | Sold Out | 2025-09-30 |